Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Visual improvement and endothelial cell counts following transepithelial corneal collagen cross-linking

Poster Details

First Author: W.Trattler USA

Co Author(s):    P. Majmudar   M. Raciti   R. Epstein   M. Mrochen   G. Perez   R. Rubinfeld

Abstract Details



Purpose:

To evaluate changes in best-correct visual acuity (BCVA), maximum keratometry, corneal astigmatism, and corneal endothelial cell density after transepithelial collagen cross-linking (CXL) for the treatment of corneal ectasia.

Setting:

Center for Excellence in Eye Care, Miami, Fl; Washington Eye Physicians and Surgeons, Chevy Chase, MD; IROC Science to Innovation AG, Zurich, Switzerland, Chicago Cornea Consultants, Chicago, Il

Methods:

Transepithelial CXL was performed using riboflavin 0.1% followed by UV-A light for 30 minutes in patients with keratoconus, pellucid degeneration, or LASIK-induced ectasia. Only eyes with corneal thickness greater than or equal to 400ṁm were treated. BCVA, maximum keratometry, corneal astigmatism, and endothelial cell counts were measured pre-CXL and at least 6 months post-CXL. Corneal endothelial cell density was measured using noncontact specular microscopy.

Results:

Two hundred fifty-one eyes completed the six-month evaluation. The mean BCVA was 0.565 ±0.276 pre-CXL and 0.629 ±452 post-CXL (P=0.028). The mean maximum keratometry measurement was 47.95 ±6.30 diopters pre-CXL and 48.07 ±6.03 diopters post-CXL (P=0.855). The mean corneal astigmatism was 4.08 ±2.73 diopters pre-CXL and 4.01 ±2.76 diopters post-CXL (P=0.834). The mean corneal endothelial cell density was 2594 ±490 cells/mm2 pre-CXL and 2721 ±404 cells/mm2 post-CXL.

Conclusions:

This study showed no a significant improvement in BCVA with no significant change in corneal endothelial cell density, maximum Keratometry or corneal astigmatism after transepithelial CXL by riboflavin/ultraviolet-A treatment for corneal ectasia.

Financial Disclosure:

... gains financially from product or procedure presented

Back to previous